secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-009744
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome reports preliminary 4Q and FY 2025 net product revenue of $196M and $638.5M, up 65% and 66% YoY
--------------------------------------------------------------------------------

- Total preliminary 4Q net product revenue $196.0M (+65% YoY); full year $638.5M (+66% YoY).
- AUVELITY net product sales: $155.1M (4Q), $507.1M (FY).
- SUNOSI net product revenue: $36.7M (4Q), $124.8M (FY).
- SYMBRAVO net product sales (launched June 2025): $4.1M (4Q), $6.6M (FY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000119312526009744/0001193125-26-009744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000119312526009744/axsm-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-009744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer